or Try an Advanced Search...

    Regeneron Stocks List

    Symbol Grade Name % Change
    SNY C Sanofi 5.90
    REGN D Regeneron Pharmaceuticals, Inc. -1.75
    ADVM F Adverum Biotechnologies, Inc. -7.85
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major
    Related Stock Lists: Colorectal Cancer Macular Degeneration Pain Adverum Biotechnologies Angiogenesis Animal Health Antibodies Asthma Atopic Dermatitis Biopharmaceutical Biotechnology Bone Breakthrough Therapy Cac 40 Cancer Cardiovascular Disease Cartilage Cholesterol Chronic Kidney Disease Clinical Development

    Related ETFs - A few ETFs which own one or more of the above listed Regeneron stocks.

    Symbol Grade Name Weight
    IBBQ D Invesco Nasdaq Biotechnology ETF 9.47
    IBB D iShares Nasdaq Biotechnology Index Fund 8.09
    BBH D Market Vectors Biotech ETF 7.74
    VIRS C Pacer BioThreat Strategy ETF 7.51
    BIB D ProShares Ultra Nasdaq Biotechnology 6.98
    View all Regeneron ETFs...
    Compare ETFs
    Compare BBH to BIB Compare IBB to BBH Compare IBB to BIB

        Regeneron Stocks Recent News

        Date Stock Title
        Apr 25 SNY AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
        Apr 25 REGN AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
        Apr 25 SNY Sanofi 2024 Q1 - Results - Earnings Call Presentation
        Apr 25 REGN Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma
        Apr 25 SNY 20 Fastest Growing Health Tech Companies in the World
        Apr 25 SNY Sanofi (SNY) Q1 2024 Earnings Call Transcript
        Apr 25 SNY Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
        Apr 25 SNY AstraZeneca Flirts With A Breakout After Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge
        Apr 25 REGN Regeneron (REGN) Reports Next Week: What You Should Expect
        Apr 25 REGN UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
        Apr 25 REGN The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power
        Apr 25 REGN Regeneron, Mammoth in pact to develop CRISPR-based gene editing therapies
        Apr 25 REGN Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
        Apr 25 REGN Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth
        Apr 25 SNY US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
        Apr 25 SNY Sanofi Sales, Profit Beat Expectations
        Apr 25 REGN Regeneron expands in gene editing with Mammoth deal
        Apr 25 SNY UPDATE 2-Sanofi profit slips on generic competition and currency effects
        Apr 25 SNY Sanofi Non-GAAP EPS of €1.78, revenue of €10.46B; reaffirms FY24 business EPS guidance
        Apr 25 SNY Sanofi profit slips on generic competition and currency effects
        Related Industries: Biotechnology Drug Manufacturers - Major
        Related Stock Lists: Colorectal Cancer Macular Degeneration Pain Adverum Biotechnologies Angiogenesis Animal Health Antibodies Asthma Atopic Dermatitis Biopharmaceutical Biotechnology Bone Breakthrough Therapy Cac 40 Cancer Cardiovascular Disease Cartilage Cholesterol Chronic Kidney Disease Clinical Development
        Regeneron

        Regeneron Pharmaceuticals, Inc. is a biotechnology company headquartered in Eastview, near Tarrytown, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities (thus the name), it branched out into the study of both cytokine and tyrosine kinase receptors.

        More about Regeneron
        Browse All Tags